Utilization of Proteomic Technologies for Precision Oncology Applications

Area of Science:

• Oncology
• Proteomics
• Molecular Biology

Background:

• Cancer is functionally a proteomic disease, driven by aberrant protein signaling networks.
• Genomic analysis alone cannot fully capture these critical protein modifications and signaling events.
• Targeted cancer therapeutics often act on these dysregulated signaling pathways.

Purpose of the Study:

• To propose a shift in cancer classification from histology to functional protein signaling architecture.
• To provide an overview of proteomic technologies for analyzing protein pathway activation in clinical specimens.
• To highlight the application of these technologies in cancer clinical studies for marker evaluation and patient stratification.

Main Methods:

• Overview of key proteomic technologies: multiplex immunoassays, phospho-specific flow cytometry, reverse phase protein microarrays, quantitative immunohistochemistry, and mass spectrometry.
• Focus on protein pathway activation analysis in clinical cancer specimens.
• Application in evaluating prognostic/predictive markers and stratifying patients for personalized treatments.

Main Results:

• Genomic derangements lead to functional protein-level alterations in cancer.
• Posttranslational modifications (e.g., phosphorylation) are key indicators of aberrant signaling.
• Proteomic technologies enable measurement of these critical events, complementing genomic data.

Conclusions:

• A functional protein signaling-based classification is essential for modern oncology.
• Proteomic technologies are vital tools for understanding cancer biology and developing personalized therapies.
• These methods facilitate the identification of biomarkers for patient stratification and treatment selection.